Pain is one of the most prevalent and difficult to manage symptoms in cancer patients, and conventional drugs present a range of adverse reactions. The development of β-cyclodextrins (β-CD) complexes has been used to avoid physicochemical and pharmacological limitations due to the lipophilicity of compounds such as p-Cymene (PC), a monoterpene with antinociceptive effects. Our aim was to obtain, characterize, and measure the effect of the complex of p-cymene and β-cyclodextrin (PC/β-CD) in a cancer pain model. Initially, molecular docking was performed to predict the viability of complex formation. Afterward, PC/β-CD was obtained by slurry complexation, characterized by HPLC and NMR. Finally, PC/β-CD was tested in a Sarcoma 180 (S180)-induced pain model. Molecular docking indicated that the occurrence of interaction between PC and β-CD is favorable. PC/β-CD showed complexation efficiency of 82.61%, and NMR demonstrated PC complexation in the β-CD cavity. In the S180 cancer pain model, PC/β-CD significantly reduced the mechanical hyperalgesia, spontaneous nociception, and nociception induced by non-noxious palpation at the doses tested (p < 0.05) when compared to vehicle differently from free PC (p > 0.05). Therefore, the complexation of PC in β-CD was shown to improve the pharmacological effect of the drug as well as reducing the required dose.

A series of twenty-five salicylic acid derivatives was synthesized and structurally characterized by ¹H and ¹³C-APT NMR and IR spectroscopic techniques, and HRMS analysis. The derivatives were subjected to biological evaluation against species of the genus Candida (C. albicans ATCC 90028, C. albicans CBS 5602, C. tropicalis CBS 94, and C. krusei CBS 573). In assays were used the broth microdilution method to determine the minimum inhibitory concentration (MIC) and verify the probable mechanism of action for antifungal activity. In the antifungal evaluation, compounds N-isobutyl-2-hidroxybenzamide (14), N-cyclohexyl-2-hydroxybenzamide (15), N-benzyl-2-hydroxybenzamide (16), N-4-methylbenzyl-2-hydroxybenzamide (17), N-4-methoxybenzyl-2-hydroxybenzamide (18), N-2,4-dimethoxybenzyl-2-hydroxybenzamide (19), N-4-fluorbenzyl-2-hiydroxybenzamide (22), and N-4-chlorobenzyl-2-hydroxybenzamide (23) were bioactive against at least one fungal strain. The compound with the best antifungal profile was N-cyclohexyl-2-hydroxybenzamide (15), which presented a MIC of 570.05 μM against most of the strains tested. The tests using ergosterol and sorbitol demonstrated that the compound does not act by altering cell wall functions or the plasmatic membrane in Candida species. The in silico analysis of 15 for antifungal activity in various biological targets suggested a probable multitarget mechanism. Therefore, the synthesis of salicylic acid derivatives resulted in compounds with a good antifungal profile.